News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

  • KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

  • KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

  • KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program

  • KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”

  • KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021

  • KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida

  • KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

  • KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

  • KemPharm to Report Third Quarter 2021 Results

  • AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

  • KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)